Home
Clinical Trials
The Stabilization Of pLaques ...

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Last Updated: 2017-08-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

13026 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-01

Study Completion Date

2014-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

NCT01977755

Focus of Study is STEMI

COMPLETED PHASE2

Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

NCT03486080

Acute Myocardial Infarction Acute Myocardial Ischemia STEMI - ST Elevation Myocardial Infarction

COMPLETED PHASE2

Thrombolysis in Myocardial Ischemia Trial (TIMI III)

NCT00000472

Angina Pectoris Cardiovascular Diseases Coronary Disease +3 more

COMPLETED PHASE3

Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus

NCT03415386

Acute Myocardial Infarction Left Ventricular Thrombus

UNKNOWN PHASE4

A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

NCT03998319

STEMI Elevated IMR (>32)

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, 6 months and every 6 months until the end of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Darapladib 160 mg

Single daily oral tablet

Group Type EXPERIMENTAL

Darapladib 160 mg

Intervention Type DRUG

Lp-PLA2 inhibitor

Standard Therapy

Intervention Type OTHER

Guideline mandated therapy for individual's condition

Placebo

Single daily oral tablet

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo administered

Standard Therapy

Intervention Type OTHER

Guideline mandated therapy for individual's condition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Darapladib 160 mg

Lp-PLA2 inhibitor

Intervention Type DRUG

Placebo

Placebo administered

Intervention Type DRUG

Standard Therapy

Guideline mandated therapy for individual's condition

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SB-480848

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed written informed consent.
* Men or women at least 18 years old (in Taiwan, at least 20 years old). Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
* Hospitalization for acute coronary syndrome (ACS) within 30 days prior to study entry.
* Clinically stable for 24 hours prior to study entry.
* A planned percutaneous coronary intervention (PCI) should be performed prior to study entry, whenever possible.
* At least one of the following:
* At least 60 years old.
* Myocardial infarction prior to the qualifying ACS event.
* Diabetes mellitus requiring treatment with medication.
* Diagnosed mild or moderate reduction in kidney function.
* Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral artery disease.

Exclusion Criteria

* ACS symptoms or lab results not believed to be caused by a narrowing or blocked coronary artery.
* No major coronary artery with a blockage of more than 50% (unless all stenoses are successfully treated by PCI).
* Planned coronary artery bypass graft (CABG) surgery, or CABG surgery performed after the qualifying ACS event and prior to study entry.
* Certain types of liver disease.
* Severe reduction in kidney function OR removal of a kidney OR kidney transplant.
* Severe heart failure.
* Blood pressure higher than normal despite lifestyle changes and treatment with medications.
* Any life-threatening disease with a life expectancy of less than 2 years (other than heart disease) that may prevent the subject from completing the study.
* Severe asthma that is poorly controlled with medication.
* Pregnancy (Note: A pregnancy test will be performed on all non-sterile women prior to study entry).
* Previous severe allergic reaction to food, medications, drink, insect stings, etc.
* Drug or alcohol abuse within the past 6 months. Mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.
* Certain medications that may interfere with the study medication (these will be identified by the study doctor).
* If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, must have a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity less than or equal to 20.0 nmol/min/mL are excluded.
* Previously took darapladib (SB-480848).
* Participation in a study of an investigational medication within the past 30 days.
* Current participation in a study of an investigational device.
* Any other reason the investigator deems the subject should not participate in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers